Evaluating JK06 for patients with advanced or metastatic cancer

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

This study is testing a new treatment called JK06 for people with advanced or metastatic cancer to see if it is safe and how well it works.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 255 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Salubris Biotherapeutics Inc (Industry-sponsored)
• Drugs / interventions: chemotherapy, radiation
• Locations: 14 sites (Antwerp and 13 other locations)
• Trial ID: NCT06667960 on ClinicalTrials.gov

What this trial studies

This Phase 1/2, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of JK06, administered intravenously to patients with unresectable locally advanced or metastatic solid tumors. The study includes a dose escalation phase to identify the maximum tolerated dose (MTD) and a cohort expansion phase to further evaluate safety and efficacy in specific tumor types. Patients will be monitored for their response to treatment and any adverse effects.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with unresectable locally advanced or metastatic solid tumors and an ECOG performance status of 1 or lower.

Not a fit: Patients with resectable tumors or those who do not meet the specified laboratory criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced cancer who currently have limited treatment choices.

How similar studies have performed: While this approach is novel in its specific application, similar studies evaluating new cancer therapies have shown promising results in the past.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18 years old.
2. Signed informed consent and willing and able to comply with study procedures and scheduled visits.
3. For Dose Escalation, patients with histologically diagnosed unresectable, locally advanced, or metastatic solid tumors.
4. Dose expansion solid tumor groups.
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
6. Life expectancy ≥ 12 weeks.
7. Measurable disease as per RECIST 1.1 criteria and documented by CT and/or MRI. Note: lesions treated previously with radiation must demonstrate clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.
8. Acceptable laboratory parameters:

   * Albumin ≥ 2.8 g/dL.
   * Platelet count ≥ 100, 000.
   * Hemoglobin ≥ 9.0 g/dL.
   * Absolute neutrophil count ≥ 1,500/μL.
   * ALT/AST ≤ 3.0 times ULN.

     \- ALT/AST ≤ 5 × ULN for patients with liver metastases.
   * Total bilirubin ≤ 1.5 ULN or ≤ 3 x ULN for patients with Gilbert's disease.
   * Direct bilirubin ≤ 1.5 ULN for patients with total bilirubin \> 1.5 ULN.
   * Creatinine ≤ 1.8 mg/dL. -Or calculated/measured creatinine clearance \> 30 mL/minute.
9. Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded \[FFPE\]) or a series of approximately 10-15 slides).
10. Consent to pre-treatment fresh tumor biopsy for patients enrolled in the back-fill part of Dose Escalation and all eligible patients enrolled in Cohort Expansion.
11. Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must have a negative serum or urine pregnancy test and be willing to use 2 forms of effective contraception throughout the study starting with screening through 217 days after the last dose of JK06.
12. Male patients with partners of childbearing potential, even if surgically sterilized (i.e., status post-vasectomy) must agree to contraceptive use from the time of consent through 217 days after treatment discontinuation.
13. Central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet certain criteria at the time of enrollment.
14. Must be willing and able to comply with clinic visits and procedures outlined in the study protocol.
15. Concurrent use of hormones for breast cancer or for non-cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitors or analogues are permitted for supportive care of patients with bone metastases.

Exclusion Criteria:

1. Patients with symptomatic or unstable CNS primary tumor or metastases and/or carcinomatous meningitis. Patients with documented treated CNS metastases stable for at least 4 weeks may be enrolled at the discretion of the investigator.
2. Major surgery within 6 weeks from treatment initiation.
3. Clinically significant cardiovascular/vascular disease ≤ 6 months before first dose.
4. Clinically significant gastrointestinal disorders.
5. Clinically significant pulmonary compromise requiring supplemental oxygen use.
6. Grade 2 or greater peripheral neuropathy at time of study entry.
7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
8. Known hypersensitivity to JK06 or any excipient.
9. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never required therapy.
10. Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment.
11. Recent or ongoing serious infection.
12. Prior systemic anti-cancer treatment:

    * For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, ≤ 2 weeks or 5 half-lives, whichever is shorter.
    * For monoclonal antibodies or similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
    * Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter.
13. Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation.
14. Pregnant or nursing.
15. Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.
16. Active pneumonitis/interstitial lung disease (ILD) or history of drug-induced or radiation-induced pneumonitis/ILD that requires ongoing systemic corticosteroid treatment or has not fully resolved at study entry.

Where this trial is running

Antwerp and 13 other locations

• Universitair Ziekenhuis Antwerpen — Antwerp, Belgium (Recruiting)
• Institut Jules Bordet — Brussels, Belgium (Recruiting)
• UZ Ghent — Ghent, Belgium (Recruiting)
• CHU UCL Namur - site Godinne — Yvoir, Belgium (Recruiting)
• NEXT Oncology Barcelona — Barcelona, Spain (Recruiting)
• START Barcelona — Barcelona, Spain (Recruiting)
• Vall d Hebron Institute of Oncology VHIO — Barcelona, Spain (Recruiting)
• CUN Madrid — Madrid, Spain (Recruiting)
• October 12th Hospital — Madrid, Spain (Recruiting)
• Next Oncology Madrid — Madrid, Spain (Recruiting)
• START Madrid — Madrid, Spain (Recruiting)
• CUN Pamplona — Pamplona, Spain (Recruiting)
• START Rioja — Rioja, Spain (Recruiting)
• Instituto de Investigación Sanitaria INCLIVA — Valencia, Spain (Recruiting)

Study contacts

• Study coordinator: Naimish Pandya, MD

Conditions Solid Tumor